Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORDER: Orelabrutinib + BR vs BR in MCL
NCT06496308Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in mantle cell lymphoma (MCL), sponsored by Ruijin Hospital. Started Jul 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06496308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496308.